Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Datadog Inc (DDOG) vs Mesoblast Limited (MESO) Price & Performance

Datadog IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Datadog Inc vs Mesoblast Limited — how do they compare? Datadog Inc trades at $246.8 (market cap $93.64B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Datadog Inc is far larger — about 43.4× Mesoblast Limited's market cap, and Datadog Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

DDOGMESO
Market Cap
$93.64B$2.16B
Sector
TechnologyTechnology
52-Week High
$288.15$20.96
52-Week Low
$102.62$12.88
Enterprise Value
$89.93B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Datadog Inc

Datadog (DDOG) trades at $233.93, up 2.02% today, but remains bearish technically with resistance near $244. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.65 versus $0.583 expected, and raised full-year revenue guidance to $4.45B-$4.47B. However, the stock faces pressure from high valuations, with a P/E of 467.86, and concerns over decelerating bookings growth from a major AI customer.

Outlook is mixed: robust revenue growth and AI momentum support long-term potential, but premium valuation and near-term usage volatility pose risks. Analyst consensus is bullish with an $288.55 price target, though insider selling and technical weakness suggest cautious near-term sentiment. Investors should balance growth prospects against execution risks and market expectations.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO